This study's is a multicenter, randomized, double‑blind, placebo‑controlled, dose‑finding study with 4 parallel groups, designed to assess the efficacy and safety of CEP‑1347 in the treatment of Parkinson’s disease. Approximately 800 patients from approximately 65 sites in the Parkinson Study Group (PSG) in the US and Canada were enrolled in this study and received 10, 25, or 50 mg bid of CEP‑1347 or a matching placebo.

Our thanks to Cephalon Inc, West Chester, PA, who has graciously agreed to share the de-identified data from the PRECEPT study.

Below find the following documents:

1. PRECEPT Protocol Synopsis
2. PRECEPT Schedule of Activites (SOA)
3. PRECEPT Annotated CRFs
4. PRECEPT Data Dictionaries
5. Instructions for downloading data
6. Links to publications
 

WE EXPECT THE PRECEPT DATA TO BE AVAILABLE SOMETIME LATER THIS YEAR.